Showing results (731-740 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|December 28, 2022
Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Formulations of 0.2-g Ibuprofen GranulesJianfen Su, Canhua Zhang, Yue Su, et al.
Clinical Pharmacology in Drug Development|December 30, 2022
Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese VolunteersFei Yuan, Jing Li, Xuening Li, et al.
Clinical Pharmacology in Drug Development|December 12, 2022
Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of AsundexianFriederike Kanefendt, Christine Brase, Sigrun Unger, et al.
Clinical Pharmacology in Drug Development|December 14, 2022
First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral SclerosisLan Gao, Peter Giannousis, Martin Thoolen, et al.
Clinical Pharmacology in Drug Development|December 8, 2022
Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein SubstrateLucy Lee, Katsuyuki Murase, Jiyuan Ma, et al.
Clinical Pharmacology in Drug Development|November 13, 2019
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy VolunteersSo Miyoshi, Sriram Krishnaswami, Shigeyuki Toyoizumi, et al.
Clinical Pharmacology in Drug Development|November 15, 2019
Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and LamivudineTeodora Pene Dumitrescu, Kavita Peddiraju, Caifeng Fu, et al.
Clinical Pharmacology in Drug Development|July 9, 2021
Lack of an Effect of Supratherapeutic Dose of Venlafaxine on Cardiac Repolarization in Healthy SubjectsRichat Abbas, Steve Riley, Sunil Nepal, et al.
Clinical Pharmacology in Drug Development|June 19, 2021
Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor AntagonistJesse C Nussbaum, Azher Hussain, Bennett Ma, et al.
Clinical Pharmacology in Drug Development|June 19, 2021
Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy SubjectsAshit Trivedi, Fady I Malik, Pegah Jafarinasabian, et al.
Pageof 136